Innate Pharma S.A. IPHA
$ 2.06
-4.63%
Annual report 2023
added 12-21-2024
Innate Pharma S.A. Balance Sheet 2011-2024 | IPHA
Annual Balance Sheet Innate Pharma S.A.
2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Debt |
- | -120 M | -189 M | -150 M | -96.5 M | -174 M | -151 M | -57.8 M | -36.7 M | -29.8 M | -33.4 M | ||
Long Term Debt |
- | - | - | 16.9 M | 14.1 M | 2.03 M | 2.42 M | 1.05 M | 1.35 M | 1.5 M | 1.5 M | 131 K | - |
Long Term Debt Current |
- | - | - | - | - | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | - | 105 M | - | 87.2 M | 95.2 M | 119 M | 174 M | 5.29 M | 6.32 M | 9.57 M | 18 M |
Total Current Liabilities |
- | - | - | - | - | - | - | - | - | - | - | - | - |
Total Liabilities |
- | - | - | 151 M | 184 M | 284 M | 169 M | 195 M | 234 M | 16.1 M | 15.6 M | 24.9 M | 33.5 M |
Deferred Revenue |
- | - | - | 12.5 M | 91.8 M | 82.1 M | 47.9 M | 54.9 M | - | 885 K | 1.26 M | 7.66 M | - |
Retained Earnings |
- | - | - | -220 M | -156 M | -135 M | -152 M | -104 M | -116 M | -110 M | -90 M | -87.1 M | -6.98 M |
Total Assets |
184 M | 208 M | 267 M | 307 M | 401 M | 451 M | 255 M | 282 M | 306 M | 90.7 M | 55.9 M | 48.3 M | 60.1 M |
Cash and Cash Equivalents |
70.6 M | 84.2 M | 104 M | 137 M | 203 M | 152 M | 99.4 M | - | - | - | - | - | - |
Book Value |
- | - | 267 M | 156 M | 217 M | 167 M | 86 M | 86.2 M | 72.1 M | 74.6 M | 40.3 M | 23.4 M | 26.6 M |
Total Shareholders Equity |
- | - | - | 156 M | 217 M | 167 M | 86 M | - | - | - | - | - | - |
All numbers in EUR currency
Quarterly Balance Sheet Innate Pharma S.A.
2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Long Term Debt |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | - | - | 80.2 M | - | 90 M | - | 106 M | - | - | - | 62.1 M | - | - | - | 87.2 M | - | - | - | 95.2 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Liabilities |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Deferred Revenue |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Retained Earnings |
- | - | - | - | - | - | - | - | - | - | - | - | -135 M | - | - | - | -139 M | - | - | - | -104 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Assets |
- | - | - | - | 267 M | - | 266 M | - | 307 M | - | - | - | 401 M | - | - | - | 451 M | - | - | - | 255 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Cash and Cash Equivalents |
- | - | - | - | 104 M | - | 104 M | - | 137 M | - | 132 M | - | 203 M | - | - | - | 152 M | - | - | - | 99.4 M | - | - | - | 176 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Book Value |
- | - | - | - | 267 M | - | 266 M | - | 307 M | - | - | - | 401 M | - | - | - | 451 M | - | - | - | 255 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Shareholders Equity |
- | - | - | - | 107 M | - | 134 M | - | 156 M | - | 208 M | - | 217 M | - | - | - | 167 M | - | - | - | 99.4 M | - | - | - | 86.2 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in EUR currency